Brief: Petros Announces Results Of OTC Label Comprehension Study For Erectile Dysfunction Drug Stendra
19/04/2022 14:21
April 19 (Reuters) - Petros Pharmaceuticals Inc PTPI.O :
* PETROS PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF
OVER-THE-COUNTER (OTC) LABEL COMPREHENSION STUDY FOR ERECTILE
DYSFUNCTION DRUG STENDRA (AVANAFIL)
* PETROS - RESULTS SUGGEST DRAFT DRUG FACTS LABELING
LANGUAGE AS
WRITTEN MAY BE APPROPRIATE FOR SUBMISSION TO FDA FOR REVIEW FOR
OTC LABELING
Source text for Eikon: ID:nGNX99CKXx
Further company coverage: PTPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Petros Pharmaceuticals
See all newsBrief: Petros Pharmaceuticals Assigns All Assets To Pt Liquidation, For Benefit Of Creditors
Brief: Petros Pharmaceuticals’ STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Brief: Petros Pharmaceuticals Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Petros Pharmaceuticals Expands Online Distribution For Prescription STENDRA(R) Through New Agreement With Lemonaid Health
Brief: Petros Pharma Announces Partnership with Idea Evolver for Rx-to-OTC Switches & Digital Launch Solutions